The Daily Biotech Pulse: Merck’s Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours:
Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2
Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.
BTIG Maintains Buy on CytomX Therapeutics, Lowers Price Target to $8
BTIG analyst Kaveri Pohlman maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $16 to $8.
Why Is GameStop Surging By Around 10%? 22 Stocks Moving In Thursday’s Pre-Market Session
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 39.6% to $0.2471 in pre-market trading after declining over 8% on Wednesday. Allena Pharmaceuticals recently announced rescheduling of special meeting to approve reverse stock split.
Mizuho Downgrades CytomX Therapeutics to Neutral, Lowers Price Target to $4
Mizuho analyst Mara Goldstein downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Neutral and lowers the price target from $16 to $4.
